Actively Recruiting
No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
Led by Kafrelsheikh University · Updated on 2025-05-13
60
Participants Needed
1
Research Sites
20 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.
CONDITIONS
Official Title
No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Both sexes
- Patients with STEMI defined as typical chest pain lasting more than 30 minutes with ST-segment elevation of more than 1 mm in at least 2 consecutive leads on an ECG or new-onset left bundle branch block
You will not qualify if you...
- Treatment with thrombolytic drugs in the previous 24 hours
- Known malignancy
- Thrombocytopenia
- End-stage liver disease
- Cardiogenic shock
- Renal failure with glomerular filtration rate less than 30 ml/min
- Contraindication for the use of tirofiban
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kafrelsheikh University
Kafr ash Shaykh, Kafrelsheikh, Egypt, 33516
Actively Recruiting
Research Team
M
Mohammed A Hammad, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here